Tectonic Therapeutic Inc (TECX)
NASDAQ:TECX
Want to see TECX full AI Analyst Report?
TECX Stock Chart & Stats
$29.51
-$0.66(-1.42%)
At close: 4:00 PM EST
$29.51
-$0.66(-1.42%)
Day’s Range― - ―
52-Week Range$14.39 - $36.03
Previous CloseN/A
Volume30.18K
Average Volume (3M)236.79K
Market Cap
$561.92M
Enterprise Value$329.66M
Total Cash (Recent Filing)$236.89M
Total Debt (Recent Filing)$4.63M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Aug 19, 2026EPS Estimate
-1.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.46
Shares Outstanding18,869,186
10 Day Avg. Volume233,845
30 Day Avg. Volume236,791
Financial Highlights & Ratios
PEG Ratio-1.69
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-6.34
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.96
Forecast
1Y Price Target
$80.75Price Target Upside173.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-5.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy SignalsPhase 1b results showed consistent improvements in pulmonary vascular resistance, pulmonary capillary wedge pressure, and cardiac output, indicating potential functional benefit and increasing the likelihood of a favorable Phase 2 outcome.
Favorable Safety ProfileIndependent safety reviews reported no safety concerns and nonhuman primate toxicology tests showed no adverse signals at the highest tested dose, reducing safety-related development risk.
Pipeline Diversification Via TX2100TX2100, a novel anti-angiogenic targeting the apelin pathway with clean preclinical data and a Phase 1a healthy-volunteer study underway, offers meaningful optionality and standalone value beyond the lead program.
Bears Say
Competitive Field SetbackA major competitor's relaxin failure has created skepticism about the relaxin mechanism and added opacity that could weigh on investor confidence for similar programs.
Financing Runway RiskHigh cash burn and a limited cash runway increase the risk of near-term financing needs that could lead to dilutive capital raises and pressure the stock.
Market Pressure And Short InterestElevated short interest combined with modest liquidity could amplify share-price volatility and make the company more vulnerable to market-driven downside during funding discussions.
Tectonic Therapeutic News
TECX FAQ
What was Tectonic Therapeutic Inc’s price range in the past 12 months?
Tectonic Therapeutic Inc lowest stock price was $14.38 and its highest was $36.03 in the past 12 months.
What is Tectonic Therapeutic Inc’s market cap?
Tectonic Therapeutic Inc’s market cap is $561.92M.
When is Tectonic Therapeutic Inc’s upcoming earnings report date?
Tectonic Therapeutic Inc’s upcoming earnings report date is Aug 19, 2026 which is in 81 days.
How were Tectonic Therapeutic Inc’s earnings last quarter?
Tectonic Therapeutic Inc released its earnings results on May 07, 2026. The company reported -$1.34 earnings per share for the quarter, missing the consensus estimate of -$1.165 by -$0.175.
Is Tectonic Therapeutic Inc overvalued?
According to Wall Street analysts Tectonic Therapeutic Inc’s price is currently Undervalued.
Does Tectonic Therapeutic Inc pay dividends?
Tectonic Therapeutic Inc does not currently pay dividends.
What is Tectonic Therapeutic Inc’s EPS estimate?
Tectonic Therapeutic Inc’s EPS estimate is -1.35.
How many shares outstanding does Tectonic Therapeutic Inc have?
Tectonic Therapeutic Inc has 18,869,186 shares outstanding.
What happened to Tectonic Therapeutic Inc’s price movement after its last earnings report?
Tectonic Therapeutic Inc reported an EPS of -$1.34 in its last earnings report, missing expectations of -$1.165. Following the earnings report the stock price went up 7.927%.
Which hedge fund is a major shareholder of Tectonic Therapeutic Inc?
Currently, no hedge funds are holding shares in TECX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tectonic Therapeutic Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$80.75 (173.64% Upside)
$80.75 (173.64% Upside)
Blogger Sentiment
Bullish
TECX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 395.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.4%
Last 30 Days ▲ 12.7%
Last 30 Days ▲ 12.7%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.12%
12-Months-Change
Fundamentals
Return on Equity
-32.33%
Trailing 12-Months
Asset Growth
-21.68%
Trailing 12-Months
Company Description
Tectonic Therapeutic Inc
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
TECX Stock 12 Month Forecast
Average Price Target
$80.75
▲(173.64% Upside)
Technical Analysis
Omeros
―
Abeona Therapeutics
―
Mereo Biopharma Group Plc
―
Foghorn Therapeutics
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
39.11% Insiders
15.13% Mutual Funds
31.66% Other Institutional Investors
8.27% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---